Cullen Capital Management LLC reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 5.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 783,385 shares of the medical instruments supplier’s stock after selling 41,335 shares during the period. Cullen Capital Management LLC owned approximately 0.28% of Becton, Dickinson and Company worth $140,226,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Edgestream Partners L.P. bought a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $3,605,000. Banco Santander S.A. bought a new position in Becton, Dickinson and Company during the third quarter valued at approximately $574,000. Silver Oak Securities Incorporated grew its position in Becton, Dickinson and Company by 28.4% during the third quarter. Silver Oak Securities Incorporated now owns 1,507 shares of the medical instruments supplier’s stock valued at $270,000 after acquiring an additional 333 shares during the last quarter. Nicholson Wealth Management Group LLC raised its stake in shares of Becton, Dickinson and Company by 5.9% during the third quarter. Nicholson Wealth Management Group LLC now owns 10,687 shares of the medical instruments supplier’s stock worth $1,913,000 after acquiring an additional 596 shares in the last quarter. Finally, Meramec Financial Planners LLC raised its stake in shares of Becton, Dickinson and Company by 19.5% during the third quarter. Meramec Financial Planners LLC now owns 612 shares of the medical instruments supplier’s stock worth $110,000 after acquiring an additional 100 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on BDX. Jefferies Financial Group restated a “buy” rating and issued a $242.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, November 5th. Royal Bank Of Canada increased their target price on shares of Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a report on Friday, November 6th. Citigroup increased their target price on shares of Becton, Dickinson and Company from $208.00 to $241.00 and gave the company a “buy” rating in a report on Friday, November 6th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $197.47.
Read Our Latest Research Report on Becton, Dickinson and Company
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,993 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $23,134,230. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,310 shares of company stock valued at $688,650 in the last three months. 0.40% of the stock is currently owned by corporate insiders.
Becton, Dickinson and Company Stock Performance
Shares of BDX stock opened at $216.33 on Tuesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. Becton, Dickinson and Company has a fifty-two week low of $140.11 and a fifty-two week high of $220.36. The stock has a 50 day moving average price of $191.53 and a two-hundred day moving average price of $170.63. The company has a market capitalization of $59.61 billion, a P/E ratio of 16.35, a PEG ratio of 3.61 and a beta of 0.22.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The firm had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. During the same quarter in the prior year, the firm posted $3.96 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Analysts expect that Becton, Dickinson and Company will post 13.21 earnings per share for the current year.
Becton, Dickinson and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be given a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Thursday, December 10th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio is currently 101.45%.
Becton, Dickinson and Company announced that its board has authorized a stock repurchase program on Thursday, November 5th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to buy up to 3.6% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
See Also
- Five stocks we like better than Becton, Dickinson and Company
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
